. Author manuscript; available in PMC: 2017 Mar 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2015 Aug 7;14(3):469–475.e2. doi: 10.1016/j.cgh.2015.07.049

Table 3.

Patient-level true positive rate (TPR) for hepatocellular carcinoma using a 6-month surveillance interval. PEB, parametric empirical Bayes; ST, single threshold.

Screening-level specificity	Cirrhosis		Advanced fibrosis
	TPR^† (N=48)		TPR^‡ (N=40)
	PEB	ST	PEB	ST
80%	83.3	70.8	95.0	77.5
85%	81.2	66.7	90.0	75.0
90%	68.8	56.2	85.0	70.0

^†

P-values from Bootstrap distribution were 0.0085, 0.0125, and 0.0075

^‡

P-values from Bootstrap distribution were 0.0120, 0.0045, and <0.0005; for screening-level specificity of 80%, 85%, and 90%, respectively.